Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

"Vascular access complications represent a significant healthcare problem, and we were impressed by the market opportunity for PRT-201 and with the quality of Proteon's team," said Dr. Steven St. Peter, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Proteon."

About PRT-201

PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit www.proteontherapeutics.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... the "Global N-acetylcysteine Industry Report 2014" ... Global N-acetylcysteine Industry Report 2014 is a professional ... the global N-acetylcysteine industry. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... August 24 Health Robotics today reported,that on ... McKesson, it,has received categorical support from virtually all ... few days since the partnership was publicly announced.,While ... on industry events, a few reactions to the ...
... , , , NEW YORK, Aug. ... the pre-disease collection, processing and long-term storage of adult stem cells for ... Technology Company with the New York Department of Taxation and Finance, for ... The Company has notified certain shareholders that, as a result of this ...
... OSLO, August 24 PCI Biotech Holding ... delivery of cancer therapeutics,today announced that the first ... with the lead candidate Amphinex(R), which uses a ... at the,University College Hospital (UCH) in London. PCI,s ...
Cached Biology Technology:Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 3Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 4NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 2NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20% 3PCI Biotech Commences Phase I/II Trials of Amphinex(R) 2
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
(Date:9/18/2014)... carbon and nitrogen comprise all spheres of our ... have caused imbalances and perturbations that resulted in ... GHGs result in climate changes which influence the ... the atmosphere. Understanding these feedback mechanisms has become ... science during the past three decades. , In ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2Transparent larvae hide opaque eyes behind reflections 2
... ROCKVILLE, MD, USA/BEIJING, CHINA -- The global fight against ... and the China National Biotec Group (CNBG) announce that ... tuberculosis (TB) vaccines. The agreement between the leading non-profit ... corporation in China signals a commitment by both to ...
... Barbara, Calif.) When UC Santa Barbara geochemist David Valentine ... bacteria blooms had consumed almost all of the deepwater methane ... people were skeptical. How, they asked, could almost all of ... disappear? In a new study published in the ...
... location and the political instability in the region have kept ... , But Hyongki Lee, a University of Houston civil engineering ... this mysterious region _ studying it from space. , Lee ... He plans to use unanalyzed satellite images to survey the ...
Cached Biology News:Aeras and CNBG sign agreement on tuberculosis vaccine R&D 2UCSB scientists say topography played key role in Deepwater Horizon disaster 2UCSB scientists say topography played key role in Deepwater Horizon disaster 3UCSB scientists say topography played key role in Deepwater Horizon disaster 4University of Houston wins NASA grant to study Congo River Basin 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: